CMR Surgical (CMR) – a global surgical robotics business –has announced that it has been awarded a significant multi-year contract by NHS Wales for implementation of the Versius® Surgical Robotic System in a National Robotics Assisted Surgery Programme.
Under the terms of the contract, four Versius systems will initially be installed across a number of hospitals in Wales, with over 1,300 patients expected to benefit from the programme annually.
Wales is the first country in the world to introduce a national surgical robotics programme, in partnership with industry, that aims to transform quality of care and outcomes for patients. As part of a national innovation drive to improve surgical outcomes for cancer patients, Versius will be used to perform procedures across Colorectal, Upper Gastrointestinal, Urological, and Gynaecology specialities. The service will be provided initially at Betsi Cadwaladr and Cardiff and Vale Health Boards, with further expansions to other health boards in the future.
CMR Surgical was appointed as the industry partner following a competitive procurement process, aligned to the National Value-Based Health Care Programme and with the goal of transforming the system of care throughout Wales. The decision is the result of an extensive process in which CMR was assessed on its ability to meet performance, quality, and pricing criteria. Versius will allow surgeons to perform complex keyhole operations precisely and accurately.
“This is a landmark move by NHS Wales and one that will bring many benefits to surgeons and patients providing them access to life changing innovation. We are proud to be part of this programme and believe countries around the world will be looking towards Wales as a potential model for implementation of surgical robotics using advanced technology,”
“We would like to thank NHS Wales for choosing us as a partner in this exciting robotics programme to address overwhelming needs for improved surgical care and outcomes for cancer patients in Wales.”
said Dr. Mark Slack, Chief Medical Officer of CMR Surgical.
“The All-Wales Robotic Assisted Surgery Network is an ambitious and important programme helping to improve outcomes for patients and the NHS in Wales. It will put Wales at the forefront of international research for the use of robotic surgical techniques. This pioneering service will also encourage specialist staff to come to Wales to train and practice”
said Eluned Morgan, Health and Social Services Minister for Wales.
“Selecting a surgical robot was a crucial step for the success of this programme. Versius will bring the benefits of advanced robotic keyhole surgery including increased operative precision, less pain, smaller scars, and less time in hospital so patients can recover quicker”
said Jared Torkington, Lead Clinician for the National Robotics Assisted Surgery Programme.
“This national programme embraces the latest innovation to improve patient outcomes and lead to efficient use of surgical teams and resources, which is critical right now.”
In partnership with Welsh Health Boards, CMR will help develop a robotic network in Wales by supporting the implementation of Versius systems, delivering training and education countrywide, supporting research, and providing the CMR global clinical registry to understand the development of patient outcomes and enable patient safety.
Cari-Anne Quinn, CEO of Life Sciences Hub Wales says
“We are delighted to support NHS Wales to accelerate innovative robotic surgery access for patients across Wales. This project with CMR is a fantastic example of how industry can partner with NHS Wales to deliver adoption on a national scale.”
CMR has successfully negotiated competitive tenders in numerous markets, through novel and flexible pricing models designed to increase access to transformative robotic assisted surgery. Versius is established as a valuable surgical tool in a number of hospitals across Europe, India, Australia, and the Middle East. Expansion of Versius within the NHS in the UK represents an important development for CMR as it continues to demonstrate significant value to patients, surgeons, and leading health systems globally.